Gout is one of the most common forms of inflammatory arthritis in South Africa, predominantly affecting middle-aged and older men. It is caused by hyperuricaemia — elevated uric acid in the blood — which leads to uric acid crystals depositing in joints, causing excruciatingly painful acute flares. Despite being highly treatable, gout is often poorly managed, leading to recurrent attacks, joint damage, and kidney complications. From a medical aid perspective, it is a non-CDL, non-PMB condition — with most costs coming from your day-to-day benefit.
What Is Gout?
Gout occurs when serum uric acid exceeds the solubility threshold (~360–420 µmol/L), causing monosodium urate (MSU) crystals to form in joints, tendons, and surrounding tissue. The classic acute gout attack begins suddenly — often waking the person at night — with intense pain, redness, warmth, and swelling, typically in the big toe (podagra), ankle, or knee. An untreated attack resolves spontaneously in 5–14 days but recurs.
Acute flare: Triggered by sudden changes in uric acid levels — following a heavy meal (organ meats, shellfish, game), alcohol (especially beer), dehydration, diuretic use, or trauma. Treatment: colchicine, NSAIDs, or corticosteroids.
Chronic tophaceous gout: After years of untreated or poorly treated gout, urate deposits form tophi — visible lumps under the skin. Joint erosion and chronic pain follow. Treatment requires long-term urate-lowering therapy (ULT).
Gout nephropathy: Uric acid crystals can deposit in the kidneys, leading to kidney stones and, in severe cases, chronic kidney disease.
South African Context
Gout is particularly common in SA males aged 40–70. Dietary risk factors prevalent in the SA diet include high purine content (meat, offal, beer) and high fructose intake (cool drinks). Diuretic use for hypertension (a very common condition in SA) raises uric acid and is a significant trigger. Many SA men with gout have comorbid hypertension, type 2 diabetes, and CKD — managing gout in this context requires careful attention to drug interactions.
Is Gout a PMB or CDL Condition?
No. Gout is not on the CDL and is not a standard PMB Diagnosis and Treatment Pair.
All gout management costs — consultations, blood tests, and medication — come from your day-to-day benefit, MSA, or ATB.
Exception: If gout-related kidney disease progresses to chronic kidney disease (CKD), the CKD is a CDL-listed condition and would be separately funded. If gout causes an acute synovial fluid crisis requiring hospitalisation (rarely), this may be funded from hospital benefits.
How Does Medical Aid Cover Gout?
| Service | Typical cover | Notes |
|---|---|---|
| GP consultation | Day-to-day | |
| Rheumatologist consultation | Day-to-day | Shortfall likely; R1,200–R2,500/visit |
| Serum uric acid blood test | Pathology benefit | R200–R400 per test |
| Synovial fluid analysis (joint aspiration — diagnosis) | Day-to-day / minor procedure | Diagnostic gold standard |
| Colchicine (acute flare) | Acute medication benefit | R200–R600 per course; very effective |
| Indomethacin / ibuprofen / diclofenac (NSAIDs) | Acute/chronic benefit | R200–R500/month; caution with renal function |
| Prednisolone (corticosteroid — for NSAID intolerance) | Acute benefit | R100–R300 per course |
| Allopurinol (urate-lowering therapy) | Acute/chronic benefit | Generic: R50–R150/month — extremely affordable |
| Febuxostat (alternative ULT) | Day-to-day / chronic benefit | More expensive than allopurinol (~R400–R700/month) |
| Lesinurad (combination ULT — rare) | Day-to-day | Not widely available in SA |
Day-to-Day Costs: What to Budget For
| Scenario | Estimated annual cost |
|---|---|
| Infrequent flares, GP-managed, allopurinol | R5,000 – R15,000 |
| Regular flares, rheumatologist-managed, allopurinol + monitoring | R15,000 – R30,000 |
| Chronic tophaceous gout + comorbidity management | R25,000 – R45,000 |
Allopurinol is remarkably cost-effective — at R50–R150/month for generic, long-term urate-lowering therapy is one of the most affordable chronic medications in the SA system. The cost burden in gout comes primarily from specialist consultations and complication management.
Gap Cover Relevance
Gap cover is not relevant for routine gout management. It would apply if joint surgery (e.g., removal of large tophi causing joint deformity, or joint replacement in end-stage tophaceous gout) is performed as an in-hospital procedure.
Key Questions to Ask Your Scheme
- Is allopurinol funded from my acute or chronic medication benefit? For long-term use, a chronic medicine dispensing arrangement (3-month supply) may be more convenient and cost-effective.
- What is my annual specialist sub-limit? If rheumatologist-managed, quarterly visits can deplete a limited specialist sub-limit.
- Are my comorbidities (hypertension, diabetes) registered on CDL? Proper CDL management of comorbidities reduces the risk of drug interactions (particularly thiazide diuretics for hypertension — these raise uric acid).
- Is febuxostat covered if allopurinol is contraindicated (renal impairment)? Ask specifically if allopurinol is not appropriate for your renal function.
Talk to Eldon
Gout is an affordable condition to manage if day-to-day benefits are structured correctly. AURA helps identify the plan with the right MSA or insured day-to-day structure for ongoing outpatient conditions.
See which plans pay for gout management →